OpGen, Inc., a Gaithersburg based molecular diagnostics company, announced today that it has launched a new molecular-based test that can quickly and reliably identify patients at risk for harboring serious disease-causing microbes that can resist even the strongest antibiotics. The Acuitas™ MDRO Gene Test is a comprehensive molecular screening tool that can directly detect as many as seven genes from one patient sample, and will help hospitals and public health officials combat some of the most critical multi-drug resistant organisms (MDROs) threatening patients in healthcare facilities.
“Drug-resistant ‘superbugs’ pose a serious and immediate threat to the world’s health and safety increasing the likelihood of prolonged illnesses, higher costs – even death,” said Evan Jones, Chairman and CEO, OpGen, Inc. “The new Acuitas MDRO Gene Test makes MDRO screening more efficient and cost-effective by delivering comprehensive, precise and actionable information to healthcare practitioners within 24 hours, assisting them in their efforts to combat and prevent the spread of these complex and potentially life-threatening infections.”